Patents by Inventor Colin Rowlings
Colin Rowlings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230011269Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: June 23, 2022Publication date: January 12, 2023Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
-
Publication number: 20210113472Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: August 31, 2020Publication date: April 22, 2021Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
-
Publication number: 20180360761Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: December 7, 2016Publication date: December 20, 2018Applicants: Ardea Biosciences, Inc., AstraZeneca ABInventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
-
Patent number: 9144548Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: October 18, 2011Date of Patent: September 29, 2015Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8460710Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: September 14, 2004Date of Patent: June 11, 2013Assignee: Shionogi, Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8425936Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: July 20, 2004Date of Patent: April 23, 2013Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8313776Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: July 20, 2004Date of Patent: November 20, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8313775Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: July 20, 2004Date of Patent: November 20, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Publication number: 20120213825Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: October 18, 2011Publication date: August 23, 2012Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8246996Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: August 20, 2004Date of Patent: August 21, 2012Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Patent number: 8062672Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: August 12, 2004Date of Patent: November 22, 2011Assignee: Shionogi Inc.Inventors: Beth A. Burnside, Henry H. Flanner, Colin Rowlings
-
Publication number: 20060193908Abstract: An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition.Type: ApplicationFiled: November 4, 2005Publication date: August 31, 2006Inventors: Beth Burnside, Colin Rowlings, Sandra Wassink, Donald Treacy, John Koleng
-
Publication number: 20060003005Abstract: A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.Type: ApplicationFiled: July 1, 2005Publication date: January 5, 2006Inventors: Bruce Cao, Sandra Wassink, Donald Treacy, Beth Burnside, Colin Rowlings, John Bonck
-
Publication number: 20050058708Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: September 14, 2004Publication date: March 17, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
-
Publication number: 20050048114Abstract: An antibiotic product is comprised of at least three dosage forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there are two delayed release dosage forms, as well as a delayed sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: August 20, 2004Publication date: March 3, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
-
Publication number: 20050037076Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: August 12, 2004Publication date: February 17, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
-
Publication number: 20050019402Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: July 20, 2004Publication date: January 27, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
-
Publication number: 20050019401Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: July 20, 2004Publication date: January 27, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings
-
Publication number: 20050019403Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: ApplicationFiled: July 20, 2004Publication date: January 27, 2005Inventors: Beth Burnside, Henry Flanner, Colin Rowlings